Advertisement

Initial experience of vericiguat add-on therapy upon fantastic four medical therapy in a patient with systolic heart failure

Published:September 14, 2022DOI:https://doi.org/10.1016/j.jccase.2022.08.012

      Abstract

      The VICTORIA trial demonstrated that vericiguat, a novel oral soluble guanylate cyclase stimulator, improved mortality and morbidity in patients with systolic heart failure, receiving conventional anti-heart failure medications. However, the clinical implication of vericiguat for those receiving guideline-directed medical therapy including sodium-glucose cotransporter 2 inhibitors: fantastic four, remains unknown. We had a patient with systolic heart failure, whose heart failure symptoms improved as well as cardiac reverse remodeling following 3-month vericugat therapy upon fantastic four medical therapy. Vericiguat might have an additional effect on patients receiving fantastic four medical therapy, although further studies are warranted to validate and establish our hypothesis.

      Learning objective

      Clinical implication of vericiguat, a novel oral soluble guanylate cyclase stimulator, in patients with systolic heart failure receiving “fantastic four” including sodium-glucose cotransporter 2 inhibitors remains uncertain. Vericiguat might have an additional effect on patients receiving fantastic four medical therapy.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Cardiology Cases
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Follmann M.
        • Griebenow N.
        • Hahn M.G.
        • Hartung I.
        • Mais F.J.
        • Mittendorf J.
        • Schafer M.
        • Schirok H.
        • Stasch J.P.
        • Stoll F.
        • Straub A.
        The chemistry and biology of soluble guanylate cyclase stimulators and activators.
        Angew Chem Int Ed Engl. 2013; 52: 9442-9462
        • Farah C.
        • Michel L.Y.M.
        • Balligand J.L.
        Nitric oxide signalling in cardiovascular health and disease.
        Nat Rev Cardiol. 2018; 15: 292-316
        • Armstrong P.W.
        • Pieske B.
        • Anstrom K.J.
        • Ezekowitz J.
        • Hernandez A.F.
        • Butler J.
        • Lam C.S.P.
        • Ponikowski P.
        • Voors A.A.
        • Jia G.
        • McNulty S.E.
        • Patel M.J.
        • Roessig L.
        • Koglin J.
        • O'Connor C.M.
        • et al.
        Vericiguat in patients with heart failure and reduced ejection fraction.
        N Engl J Med. 2020; 382: 1883-1893
        • McMurray J.J.V.
        • Solomon S.D.
        • Inzucchi S.E.
        • Kober L.
        • Kosiborod M.N.
        • Martinez F.A.
        • Ponikowski P.
        • Sabatine M.S.
        • Anand I.S.
        • Belohlavek J.
        • Bohm M.
        • Chiang C.E.
        • Chopra V.K.
        • de Boer R.A.
        • Desai A.S.
        • et al.
        Dapagliflozin in patients with heart failure and reduced ejection fraction.
        N Engl J Med. 2019; 381: 1995-2008
        • Tsutsui H.
        • Ide T.
        • Ito H.
        • Kihara Y.
        • Kinugawa K.
        • Kinugawa S.
        • Makaya M.
        • Murohara T.
        • Node K.
        • Saito Y.
        • Sakata Y.
        • Shimizu W.
        • Yamamoto K.
        • Bando Y.
        • Iwasaki Y.K.
        • et al.
        JCS/JHFS 2021 guideline focused update on diagnosis and treatment of acute and chronic heart failure.
        Circ J. 2021; 85: 2252-2291
        • Bauersachs J.
        Heart failure drug treatment: the fantastic four.
        Eur Heart J. 2021; 42: 681-683
        • Gheorghiade M.
        • Greene S.J.
        • Butler J.
        • Filippatos G.
        • Lam C.S.
        • Maggioni A.P.
        • Ponikowski P.
        • Shah S.J.
        • Solomon S.D.
        • Kraigher-Krainer E.
        • Samano E.T.
        • Muller K.
        • Roessig L.
        • Pieske B.
        SOCRATES-REDUCED investigators and coordinators. Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction: the SOCRATES-REDUCED randomized trial.
        JAMA. 2015; 314: 2251-2262
        • Swedberg K.
        • Komajda M.
        • Bohm M.
        • Borer J.S.
        • Ford I.
        • Dubost-Brama A.
        • Lerebours G.
        • Tavazzi L.
        • Investigators S.H.I.F.T.
        Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study.
        Lancet. 2010; 376: 875-885